Actively Recruiting

Age: 18Years +
All Genders
ID07574697

Genetic Susceptibility to AF-Induced Cardiomyopathy

Led by Barts & The London NHS Trust · Updated on 2026-05-08

299

Participants Needed

1

Research Sites

8 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Atrial Fibrillation (AF) is a common heart rhythm problem affecting many adults over 45. While most tolerate AF well, some develop heart failure due to weakened heart pumping. This research aims to understand why some people with AF develop heart failure by studying specific genetic differences in patients who develop heart failure triggered by AF compared to those who do not. The study will analyze genetic variants linked to heart muscle disease in three groups: patients with AF-induced heart failure who recover after treatment, patients with AF who do not develop heart failure, and patients with AF-related heart failure who do not recover after treatment. The study will include 92 patients with AF-induced heart failure who improve after treatments such as catheter ablation or cardioversion, 184 patients with AF but preserved heart function, and 23 patients with AF and heart failure who do not improve after treatment. Researchers will test a selected set of genetic variants known to cause heart muscle disease to find differences among these groups. This focused approach aims to be cost-effective and avoid unclear genetic results. Participants will undergo baseline genetic testing on one day to identify these genetic variants. The main measure is the prevalence of these gene variants in the AF-induced heart failure group compared to controls. The findings could help doctors identify patients at risk for heart failure during AF, guide treatment decisions, and suggest family screening when needed. The study is sponsored by Barts & The London NHS Trust and will collect data until May 2027.

CONDITIONS

Brief Title

AIC Genotyping Study

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Persistent atrial fibrillation before catheter ablation or cardioversion
  • Left ventricular ejection fraction (LVEF) 40% or less during rate-controlled AF for cases
  • LVEF 55% or higher during rate-controlled AF for negative controls
  • LVEF 40% or less during rate-controlled AF with persistent LV dysfunction for positive controls
  • LVEF improvement to 55% or higher in sinus rhythm after treatment for cases
  • No atrial fibrillation detected after treatment beyond the blanking period
  • No new or increased heart failure medication after treatment
Not Eligible

You will not qualify if you...

  • Alternative causes for left ventricular dysfunction such as ischemic or non-ischemic cardiomyopathy before AF diagnosis, primary valve disease, or inherited cardiomyopathy
  • Pregnancy during atrial fibrillation or in the 12 months before left ventricular dysfunction onset
  • Alcohol intake exceeding 21 units per week
  • History of cardiotoxic chemotherapy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - 1 day

Participants undergo baseline genetic testing and heart function assessments to identify specific genetic variations and heart status.

1 baseline visit (in-person)

Long-term Monitoring

Duration - Up to several years until study completion

Participants are observed over time to monitor heart function and the presence of atrial fibrillation after treatment.

Follow-up visits as scheduled depending on participant group

Trial Site Locations

Total: 1 location

1

St Bartholomew's Hospital, Barts Health NHS Trust

London, United Kingdom, EC1A 7BE

Actively Recruiting

Loading map...

Research Team

N

Nikhil Ahluwalia, MBBS, PhD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Similar Trials

A Bioequivalence Study of Two Formulations of HRS-1893 Table...

Cardiomyopathy

Actively Recruiting

1 location

A Global Randomized Trial Comparing Pulsed Field Ablation of...

Atrial Fibrillation (AF)

Actively Recruiting

41 locations

A Preventive, Multidisciplinary Primary Care Intervention Or...

Vascular Disease

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here